Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug 26:15:897-912.
doi: 10.2147/OTT.S285758. eCollection 2022.

Overcoming Obstacles in Liquid Biopsy Developments for Prostate Cancer

Albert Jang  1 , Grant P Rauterkus  2 , Ulka N Vaishampayan #  3 , Pedro C Barata #  1   4   5
Affiliations
Review

Overcoming Obstacles in Liquid Biopsy Developments for Prostate Cancer

Albert Jang et al. Onco Targets Ther. .

Abstract

Prostate cancer is one of the most common malignancies in men. Over time, it can metastasize and become lethal once it exhausts hormonal therapies and transitions into castration-resistant prostate cancer (CRPC). Several therapies have been recently approved for advanced prostate cancer, but identifying biomarkers for current treatments and searching for more effective treatments are urgently needed. Liquid biopsy is a powerful tool for isolating genetic material, proteins, and whole tumor cells from the blood. In recent decades, this technology has rapidly advanced, allowing for better insights into the pathogenesis and treatment response in different stages of prostate cancer. In this review, we summarize important clinical studies involving liquid biopsies in prostate cancer with a focus on advanced disease, notably regarding circulating tumor DNA, circulating tumor cells, and exosomes. We highlight the progress and the challenges that still exist for these technologies. Finally, we discuss promising avenues that will further expand the importance of liquid biopsy in the care for prostate cancer patients.

Keywords: advanced prostate cancer; circulating tumor DNA; circulating tumor cells; exosomes; liquid biopsy.

PubMed Disclaimer

Conflict of interest statement

Dr Ulka N Vaishampayan reports personal fees from AAA, grants from BMS, grants, personal fees from Merck, personal fees from Sanofi, personal fees from Exelixis, personal fees from Bayer, personal fees from Aveo, personal fees from Gilead, personal fees from Pfizer, outside the submitted work. Dr Pedro C Barata reports (Institutional) consulting services from EMD Serono, Astellas, Eisai, Janseen, (Institutional) consulting services; (Institutional) educational grant from Dendreon, (Institutional) consulting services from Pfizer, (Institutional) consulting services; (Institutional) contracted research from Seagen, (Institutional) consulting services from BMS and from Bayer, (Institutional) consulting services; (Institutional) contracted research from Guardant and from BlueEarth Diagnostics, (Institutional) consulting services from Myovant, (Institutional) consulting services; (Institutional) contracted research from Caris Life Sciences, during the conduct of the study. The authors report no conflicts of interest in this work.

References

    1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. doi:10.3322/caac.21708 - DOI - PubMed
    1. Key statistics for prostate cancer; [updated January 12, 2022]. Available from: https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html. Accessed March 31, 2022.
    1. Halabi S, Kelly WK, Ma H, et al. Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer. J Clin Oncol. 2016;34(14):1652–1659. - PMC - PubMed
    1. van Dessel LF, van Riet J, Smits M, et al. The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact. Nat Commun. 2019;10(1):5251. - PMC - PubMed
    1. FDA approves olaparib for HRR gene-mutated metastatic castration-resistant prostate cancer; 2020. [updated May 20, 2020]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-appro.... Accessed April 1, 2022.

LinkOut - more resources